Ultragenyx Pharmaceutical RARE Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -83.8%-4.2pp | -79.5%+6.8pp | -86.4%-3.5pp | -82.9%+4.2pp | -87%+8.7pp | |
| Net margin | -90.9%-5.5pp | -85.5%+6.5pp | -92%-4.6pp | -87.4%+5.7pp | -93.1%+8.5pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×+0.1× | 0.4×0.0× | 0.5×0.0× | 0.4×0.0× | 0.5×+0.1× | |
| Liquidity | ||||||
| Current ratio | 2×-0.5× | 2.5×+0.6× | 1.9×-0.6× | 2.5×+0.1× | 2.4×0.0× | |
| Per Share | ||||||
| Book value per share | -$2.35-189% | -$0.81-984% | $0.09-94.0% | $1.54+2.8% | $1.50-46.9% | |
| Valuation | ||||||
| Market capitalization | $2.06B-7.2% | $2.22B-23.5% | $2.9B-17.5% | $3.51B+3.3% | $3.4B-12.5% | |
| Price / sales | 3.1×-0.2× | 3.3×-1.3× | 4.6×-1.2× | 5.8×0.0× | 5.8×-1.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ultragenyx Pharmaceutical's profit margins?
- Ultragenyx Pharmaceutical (RARE) runs a 97.2% gross margin and a -83.8% operating margin, with a -90.9% net margin.
- Where do Ultragenyx Pharmaceutical's ratios come from?
- Every ratio is computed from Ultragenyx Pharmaceutical's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.